Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension

Haiyang Tang, Kang Wu, Jian Wang, Sujana Vinjamuri, Yali Gu, Shanshan Song, Ziyi Wang, Qian Zhang, Angela Balistrieri, Ramon J. Ayon, Franz Rischard, Rebecca Vanderpool, Jiwang Chen, Guofei Zhou, Ankit Desai, Stephen M. Black, Joe GN Garcia, Jason Yuan, Ayako Makino

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Concentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial smooth muscle cells is an important pathological cause for the elevated pulmonary vascular resistance reported in patients with pulmonary arterial hypertension. We identified a differential role of mammalian target of rapamycin (mTOR) complex 1 and complex 2, two functionally distinct mTOR complexes, in the development of pulmonary hypertension (PH). Inhibition of mTOR complex 1 attenuated the development of PH; however, inhibition of mTOR complex 2 caused spontaneous PH, potentially due to up-regulation of platelet-derived growth factor receptors in pulmonary arterial smooth muscle cells, and compromised the therapeutic effect of the mTOR inhibitors on PH. In addition, we describe a promising therapeutic strategy using combination treatment with the mTOR inhibitors and the platelet-derived growth factor receptor inhibitors on PH and right ventricular hypertrophy. The data from this study provide an important mechanism-based perspective for developing novel therapies for patients with pulmonary arterial hypertension and right heart failure.

Original languageEnglish (US)
Pages (from-to)744-762
Number of pages19
JournalJACC: Basic to Translational Science
Volume3
Issue number6
DOIs
StatePublished - Dec 1 2018

Fingerprint

Pulmonary Hypertension
Sirolimus
Platelet-Derived Growth Factor Receptors
Lung
Smooth Muscle Myocytes
Right Ventricular Hypertrophy
Therapeutic Uses
mechanistic target of rapamycin complex 1
TOR complex 2
Vascular Resistance
Blood Vessels
Up-Regulation
Therapeutics
Heart Failure

Keywords

  • mTOR
  • pulmonary hypertension
  • Raptor
  • Rictor
  • right ventricle

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension. / Tang, Haiyang; Wu, Kang; Wang, Jian; Vinjamuri, Sujana; Gu, Yali; Song, Shanshan; Wang, Ziyi; Zhang, Qian; Balistrieri, Angela; Ayon, Ramon J.; Rischard, Franz; Vanderpool, Rebecca; Chen, Jiwang; Zhou, Guofei; Desai, Ankit; Black, Stephen M.; Garcia, Joe GN; Yuan, Jason; Makino, Ayako.

In: JACC: Basic to Translational Science, Vol. 3, No. 6, 01.12.2018, p. 744-762.

Research output: Contribution to journalArticle

Tang, H, Wu, K, Wang, J, Vinjamuri, S, Gu, Y, Song, S, Wang, Z, Zhang, Q, Balistrieri, A, Ayon, RJ, Rischard, F, Vanderpool, R, Chen, J, Zhou, G, Desai, A, Black, SM, Garcia, JGN, Yuan, J & Makino, A 2018, 'Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension', JACC: Basic to Translational Science, vol. 3, no. 6, pp. 744-762. https://doi.org/10.1016/j.jacbts.2018.08.009
Tang, Haiyang ; Wu, Kang ; Wang, Jian ; Vinjamuri, Sujana ; Gu, Yali ; Song, Shanshan ; Wang, Ziyi ; Zhang, Qian ; Balistrieri, Angela ; Ayon, Ramon J. ; Rischard, Franz ; Vanderpool, Rebecca ; Chen, Jiwang ; Zhou, Guofei ; Desai, Ankit ; Black, Stephen M. ; Garcia, Joe GN ; Yuan, Jason ; Makino, Ayako. / Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension. In: JACC: Basic to Translational Science. 2018 ; Vol. 3, No. 6. pp. 744-762.
@article{1d6f5fc1b3ae431ead864d93bf81b3a0,
title = "Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension",
abstract = "Concentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial smooth muscle cells is an important pathological cause for the elevated pulmonary vascular resistance reported in patients with pulmonary arterial hypertension. We identified a differential role of mammalian target of rapamycin (mTOR) complex 1 and complex 2, two functionally distinct mTOR complexes, in the development of pulmonary hypertension (PH). Inhibition of mTOR complex 1 attenuated the development of PH; however, inhibition of mTOR complex 2 caused spontaneous PH, potentially due to up-regulation of platelet-derived growth factor receptors in pulmonary arterial smooth muscle cells, and compromised the therapeutic effect of the mTOR inhibitors on PH. In addition, we describe a promising therapeutic strategy using combination treatment with the mTOR inhibitors and the platelet-derived growth factor receptor inhibitors on PH and right ventricular hypertrophy. The data from this study provide an important mechanism-based perspective for developing novel therapies for patients with pulmonary arterial hypertension and right heart failure.",
keywords = "mTOR, pulmonary hypertension, Raptor, Rictor, right ventricle",
author = "Haiyang Tang and Kang Wu and Jian Wang and Sujana Vinjamuri and Yali Gu and Shanshan Song and Ziyi Wang and Qian Zhang and Angela Balistrieri and Ayon, {Ramon J.} and Franz Rischard and Rebecca Vanderpool and Jiwang Chen and Guofei Zhou and Ankit Desai and Black, {Stephen M.} and Garcia, {Joe GN} and Jason Yuan and Ayako Makino",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.jacbts.2018.08.009",
language = "English (US)",
volume = "3",
pages = "744--762",
journal = "JACC: Basic to Translational Science",
issn = "2452-302X",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension

AU - Tang, Haiyang

AU - Wu, Kang

AU - Wang, Jian

AU - Vinjamuri, Sujana

AU - Gu, Yali

AU - Song, Shanshan

AU - Wang, Ziyi

AU - Zhang, Qian

AU - Balistrieri, Angela

AU - Ayon, Ramon J.

AU - Rischard, Franz

AU - Vanderpool, Rebecca

AU - Chen, Jiwang

AU - Zhou, Guofei

AU - Desai, Ankit

AU - Black, Stephen M.

AU - Garcia, Joe GN

AU - Yuan, Jason

AU - Makino, Ayako

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Concentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial smooth muscle cells is an important pathological cause for the elevated pulmonary vascular resistance reported in patients with pulmonary arterial hypertension. We identified a differential role of mammalian target of rapamycin (mTOR) complex 1 and complex 2, two functionally distinct mTOR complexes, in the development of pulmonary hypertension (PH). Inhibition of mTOR complex 1 attenuated the development of PH; however, inhibition of mTOR complex 2 caused spontaneous PH, potentially due to up-regulation of platelet-derived growth factor receptors in pulmonary arterial smooth muscle cells, and compromised the therapeutic effect of the mTOR inhibitors on PH. In addition, we describe a promising therapeutic strategy using combination treatment with the mTOR inhibitors and the platelet-derived growth factor receptor inhibitors on PH and right ventricular hypertrophy. The data from this study provide an important mechanism-based perspective for developing novel therapies for patients with pulmonary arterial hypertension and right heart failure.

AB - Concentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial smooth muscle cells is an important pathological cause for the elevated pulmonary vascular resistance reported in patients with pulmonary arterial hypertension. We identified a differential role of mammalian target of rapamycin (mTOR) complex 1 and complex 2, two functionally distinct mTOR complexes, in the development of pulmonary hypertension (PH). Inhibition of mTOR complex 1 attenuated the development of PH; however, inhibition of mTOR complex 2 caused spontaneous PH, potentially due to up-regulation of platelet-derived growth factor receptors in pulmonary arterial smooth muscle cells, and compromised the therapeutic effect of the mTOR inhibitors on PH. In addition, we describe a promising therapeutic strategy using combination treatment with the mTOR inhibitors and the platelet-derived growth factor receptor inhibitors on PH and right ventricular hypertrophy. The data from this study provide an important mechanism-based perspective for developing novel therapies for patients with pulmonary arterial hypertension and right heart failure.

KW - mTOR

KW - pulmonary hypertension

KW - Raptor

KW - Rictor

KW - right ventricle

UR - http://www.scopus.com/inward/record.url?scp=85059098492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059098492&partnerID=8YFLogxK

U2 - 10.1016/j.jacbts.2018.08.009

DO - 10.1016/j.jacbts.2018.08.009

M3 - Article

VL - 3

SP - 744

EP - 762

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

SN - 2452-302X

IS - 6

ER -